November 22nd 2024
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
2024 Neuromuscular Summit
November 20, 2024
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Study finds youth with developmental disabilities less likely to access reproductive health care
May 22nd 2024A recent study reveals that adolescents with autism and other developmental disabilities have fewer visits to obstetrician-gynecologists and lower hormonal contraceptive use compared to their typically developing peers, highlighting a need for improved reproductive health services.
Read More
Mail-order dispensing of mifepristone for medication abortion found effective
May 13th 2024A recent study revealed that mail-order pharmacy dispensing of mifepristone for medication abortion proves effective and satisfactory, highlighting a potential avenue for expanding access to reproductive healthcare.
Read More
Contemporary understanding of breast cancer risk with combined oral contraceptives
April 2nd 2024Unveiling the intricate relationship between combined oral contraceptive use and breast cancer risk, navigating through research insights and clinical implications for informed patient counseling.
Read More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
Impact of serum estradiol decline before hCG-triggering on IVF outcomes
March 13th 2024A recent study delves into how serum estradiol decline preceding human chorionic gonadotropin administration affects in vitro fertilization outcomes, particularly among patients without oral contraceptive pretreatment, shedding light on the importance of monitoring during controlled ovarian hyperstimulation.
Read More
New guidelines revealed for no-cost FDA-approved contraceptives
January 23rd 2024The Biden-Harris administration, has released comprehensive guidance through Frequently Asked Questions to eliminate barriers to contraception, ensuring access to FDA-approved contraceptives at no cost, following President Biden's 2023 Executive Order.
Read More
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More